Aspirin and Clopidogrel Timing and Dosing Prior to PCI
For patients undergoing PCI, administer aspirin 81-325 mg immediately if not already on therapy, and give clopidogrel 600 mg as a loading dose at least 2 hours before the procedure (preferably ≥6 hours, ideally 15-24 hours for optimal effect). 1, 2
Aspirin Dosing
Pre-procedure:
- Patients already on daily aspirin: Continue with 81-325 mg before PCI 2
- Patients NOT on aspirin: Give non-enteric aspirin 325 mg before PCI 2
Post-procedure:
- Continue aspirin 81 mg daily indefinitely (preferred over higher maintenance doses) 2
Clopidogrel Dosing and Timing
For Acute Coronary Syndrome (ACS):
- Loading dose: 300 mg (FDA-approved) 3
- However, 600 mg is recommended by guidelines for both ACS and non-ACS patients undergoing PCI 2
- Continue 75 mg daily after loading 2, 3
For Elective PCI (Stable CAD):
- 600 mg loading dose once coronary anatomy is known and PCI decision is made 1
- Timing: Preferably ≥2 hours before procedure 1
- Optimal timing: ≥6 hours, ideally 15-24 hours for maximal antiplatelet effect 4, 5
Critical Timing Considerations
The evidence clearly demonstrates a time-dependent effect for clopidogrel pretreatment:
- <6 hours: Minimal benefit over no pretreatment 4
- 6-15 hours: Emerging benefit, with 38.6% relative risk reduction when given ≥6 hours before PCI 4
- ≥15 hours: Significant benefit (58.8% reduction in adverse events, p=0.028) 5
- 24-28 hours: Maximal antiplatelet effect achieved 6, 5
Important caveat: If PCI must be performed urgently (within hours), initiate the 600 mg loading dose as soon as possible, recognizing that full antiplatelet effect will not be achieved but some benefit still occurs 2, 3. Without a loading dose, establishment of antiplatelet effect is delayed by several days 3.
Special Situations
Post-fibrinolytic therapy:
- 300 mg clopidogrel if within 24 hours of fibrinolysis
- 600 mg if >24 hours after fibrinolysis 2
European guidelines note: Pretreatment with clopidogrel when coronary anatomy is unknown carries a Class III recommendation (not recommended) in stable CAD, but may be considered (Class IIb) in patients with high probability of significant CAD 1.